Medications for Uterine Cervical Neoplasms

5 results

  • Aminocaproic acid (aminocaproic acid)

    (AMINOCAPROIC ACID)
    PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS
    Usage: Aminocaproic acid is indicated for enhancing hemostasis in cases of bleeding due to fibrinolysis, especially following heart surgeries, in hematological disorders, abruptio placentae, hepatic cirrhosis, and certain cancers. It also addresses excessive urinary tract bleeding related to surgical or nonsurgical hematuria.

  • Indocyanine green (indocyanine green and water)

    (Indocyanine Green and Water)
    Renew Pharmaceuticals Limited
    Usage: Indocyanine Green is indicated for fluorescence imaging of vessels, blood flow, and tissue perfusion in various surgeries; visualization of extrahepatic biliary ducts; lymphatic mapping in cervical and uterine cancer; and ophthalmic angiography in adults and pediatric patients, ages 1 month and older.

  • Spy elite kit (indocyanine green)

    (indocyanine green)
    Novadaq Technologies Inc
    Usage: SPY AGENT GREEN is indicated for fluorescence imaging of micro- and macro-vasculature, blood flow, and tissue perfusion in various surgical procedures, visualization of extrahepatic biliary ducts in patients aged 12 and older, and lymphatic mapping in cervical, uterine, and breast cancer surgeries in adults.

  • Topotecan (topotecan hydrochloride)

    (Topotecan Hydrochloride)
    Meitheal Pharmaceuticals Inc.
    Usage: Topotecan Hydrochloride for Injection is indicated for the treatment of metastatic ovarian cancer after chemotherapy failure, small cell lung cancer post-first-line chemotherapy progression, and in combination with cisplatin for Stage IV-B or recurrent cervical cancer not suitable for curative treatment.

  • Topotecan hydrochloride (topotecan hydrochloride)

    (TOPOTECAN HYDROCHLORIDE)
    Fresenius Kabi USA, LLC
    Usage: Topotecan hydrochloride is indicated for the treatment of metastatic ovarian cancer after chemotherapy progression, small cell lung cancer in platinum-sensitive patients post-first-line treatment, and, in combination with cisplatin, for Stage IV-B or recurrent cervical cancer not suitable for curative treatment.